The Financing Desk: What a Medical Credit Card Actually Costs When You Pay for Cosmetic Surgery

There is a moment near the end of the aesthetic consultation that gets almost no editorial attention and deserves quite a lot of it. The surgeon leaves. Someone else comes in, usually with a printed quote and a tablet, and the conversation stops being clinical and starts being financial. The number is large. The person holding the tablet has a solution for the number, and the solution takes about four minutes to apply for.

That solution is very often a medical credit card with a promotional period attached. It is presented as a payment plan. It is, in the most common configuration, a deferred interest revolving credit product carrying a purchase rate north of thirty percent, and the difference between those two descriptions is where a meaningful amount of money changes hands every year in this industry.

None of this is hidden. All of it is disclosed. It is simply disclosed at the worst possible moment, to a patient who has just spent an hour being told that the thing they want is achievable, and who is now motivated to make the arithmetic work.

Cosmetic surgery is a cash-pay market, which makes it a lending market

The short answer: elective aesthetic procedures are almost never covered by insurance, so the entire sector runs on out-of-pocket payment, and where there is a large out-of-pocket payment there is a financing industry attached to it.

This is the structural fact that explains everything downstream. A knee replacement gets adjudicated by a payer. A rhinoplasty for appearance does not. The patient is the payer, the amount is typically four or five figures, and it is usually due before the operating room is booked rather than after.

That creates an obvious commercial problem for practices and an obvious commercial opportunity for lenders. The result is a mature, competitive patient financing market: CareCredit, which is issued by Synchrony and is the largest of them, along with Alphaeon Credit, Cherry, PatientFi, Prosper Healthcare Lending, and a rotating cast of newer entrants. Most aesthetic practices of any size are enrolled with at least one and often several.

The relevant point for a patient is not that financing exists. Financing an elective procedure over a defined term at a stated rate can be a perfectly rational decision. The point is that the specific product most often placed in front of you has a structure that behaves very differently depending on one variable: whether you finish paying by a particular date.

Deferred interest is not a zero-interest loan, and the distinction is the whole story

The short answer: with a genuine zero-percent promotional rate, no interest accrues during the promotional window; with deferred interest, interest accrues from day one and is simply not charged unless you miss the deadline, at which point the entire accrued amount is added retroactively on the full original purchase.

Read that twice, because the industry language is engineered to blur it. "No interest if paid in full within 12 months" is not the same sentence as "no interest for 12 months." The first is a conditional waiver. The second is a rate.

CareCredit's own disclosures are clear about the mechanics: promotional financing is offered in 6, 12, 18, and 24 month terms on qualifying purchases of two hundred dollars or more, interest accrues from the purchase date during that period, and it is waived only if the promotional balance is paid in full by the end of the term. The purchase APR for new accounts has been disclosed at 32.99 percent. If the balance is not cleared in time, that rate is applied to the full original promotional purchase, calculated back to the day of the transaction.

There is a second mechanic that catches more people than the first. The required minimum monthly payment on these accounts is not calculated to retire the promotional balance by the promotional deadline. CareCredit discloses this directly: the minimum payment may or may not pay off the promo balance before the promotional period ends, depending on the purchase amount, the promotional length, and payment allocation. A patient who pays exactly what the statement asks for, every month, on time, can still arrive at month twelve with a balance and a retroactive interest bill. Perfect compliance with the stated minimum is not a defense.

"

"No interest if paid in full within 12 months" is a conditional waiver, not a rate. Miss the date by a dollar and the interest was always running.

"

The federal numbers on what this costs

The short answer: the Consumer Financial Protection Bureau found that between 2018 and 2020, consumers used deferred interest medical credit cards and installment products for nearly 23 billion dollars in healthcare expenses and incurred about 1 billion dollars in deferred interest over those three years.

Those figures come from the CFPB's May 2023 report on medical credit cards and financing plans, which examined the market and the terms attached to a sample of these products. Two of its other findings are more useful to an individual patient than the headline totals.

First, the payoff rate. Across that period, the share of promotional balances paid off within the promotional window sat just under 80 percent, dropping to 76 percent in 2020. Turn that around and it says roughly one in five people who took a deferred interest promotion did not finish in time and got the retroactive bill. That is not a rare edge case. It is the ordinary experience of a substantial minority of users.

Second, the pricing. The CFPB noted that interest rates on these medical financing products commonly exceed 25 percent and generally run higher than rates on general purpose credit cards. Which produces an uncomfortable comparison: for a patient with reasonable credit, an ordinary card, a credit union personal loan, or a plain installment loan at a disclosed fixed rate may cost less than the specialty product offered in the treatment room, precisely because the specialty product's headline appeal is conditional and its fallback rate is not competitive.

Regulators noticed. In July 2023 the CFPB, the Department of Health and Human Services, and the Treasury Department jointly requested information on medical payment products, specifically citing concerns about deferred interest and about these products being marketed to patients in clinical settings at the point of care. The scrutiny has not eliminated the product. It has made the disclosures somewhat louder.

The practice is not a neutral party

The short answer: when a patient uses third-party financing, the lender pays the practice up front and takes a merchant discount fee out of the proceeds, and longer promotional terms generally cost the practice more, which means the plan you are steered toward is not selected on your economics alone.

This is the part patients almost never hear articulated. The clinic is not simply doing you a favor by processing paperwork. It is a merchant in a payments relationship. It gets paid immediately and in full, the lender absorbs the collection risk, and the lender is compensated by a fee deducted from the practice's payout plus whatever interest the patient eventually pays. Industry comparisons of patient financing vendors describe merchant discount fees ranging from low single digits to well into double digits depending on the plan length and the provider.

That structure creates ordinary, legal, and entirely predictable incentives. A practice with a high-fee long-term plan and a low-fee short-term plan is not indifferent between them. A practice that closes more cases when financing is offered has a reason to offer it early and often. And a patient coordinator whose compensation is tied to booked cases is a salesperson with a clinical vocabulary, which is a dynamic we have written about in the context of who is actually performing your injections and one that applies just as cleanly to the financing desk.

None of this makes financing wrong. It makes the person explaining it to you an interested party. The correct response is not suspicion, it is documentation. Ask what the practice receives. A straightforward answer is a good sign about the practice generally.

What the loan does not cover

The short answer: financing covers the quoted procedure, and the quoted procedure is frequently not the total cost of the episode, because revisions, complications, extended recovery, and second-stage work sit outside the number on the tablet.

This is where the financing question stops being about interest rates and becomes about surgical planning. A promotional balance is sized to a quote. We have argued before that the quote is not the price, and the gap shows up in specific places: anesthesia and facility fees billed separately, garments and post-operative supplies, time away from work, and the cost of managing a complication that is nobody's fault.

Then there is revision. Some fraction of aesthetic operations need a second procedure, and the revision policy is a separate document from the financing agreement. A practice may waive its surgeon fee on a revision and still charge facility and anesthesia. Others charge in full. The revision consult economy exists because these situations are common enough to sustain surgeons who specialize in them. A patient who has financed to the limit of what they can service has no capacity left for the second operation, which is precisely when they need it.

The maintenance question is the same question on a longer timeline. Injectables, resurfacing, and most body contouring results are rented rather than owned, a point we laid out in detail on how long results actually last. Financing the first round of an ongoing expense at above thirty percent, and then financing the second round on top of a balance that has not cleared, is how patients end up with a revolving balance attached to a face they have to keep maintaining.

The honest summary

Financing elective surgery is a normal financial decision and there is nothing disreputable about it. Amortizing a large one-time cost over a defined term at a disclosed rate is what credit is for.

What is not normal is the specific product that dominates this market. A deferred interest medical credit card is presented as a payment plan and behaves as one only if you finish on schedule. If you do not, and the CFPB's data says roughly one in five people do not, the interest was accruing the entire time at a rate above thirty percent and it lands in a single retroactive charge on the full original amount. The minimum payment printed on your statement will not necessarily save you from that.

So do three things. Get the term sheet before the consultation ends, not during it, and read it somewhere other than the clinic. Price the alternatives, because a credit union installment loan or an ordinary card at a lower fixed rate frequently beats the specialty product on total cost. And size the borrowing to the episode rather than the quote, leaving room for the revision, the second stage, and the maintenance that most of these procedures require.

The number on the tablet is the beginning of the cost, not the end of it. Anyone who tells you otherwise is closing.